Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Alys Hall who wrote (923)	12/22/1997 2:06:00 PM
From: EZLibra	Respond to of 3702

Alys, someone e-mailed the following to me from aol. It's what I call common sense; "The biotech index continued to consolidate over the last two months although it is flirting with support as I write. More significant is the continued bashing of Techniclone here and on SI. It seems apparent to me that ALL the bad news has been discounted and there is little left that would surprise the market on the downside; except those with hidden agendas. I liken this sentiment to that of IBM back in 1994 following the dividend cut in February when the stock was trading at $50 (unadjusted for 2/1 split). It finally bottomed in the low 40's. Eastman Kodak is another case in point; how much more bad news can be unexpected to the market. It is likely a good accumulation stock at these levels. All stockholders will benefit from the naming of a new CEO including existing management. This stock has bottomed year after year after year in late fall. It should be no different this time around except that there will be at least two ongoing trials next year, hopefully with interim reports that may act to generate new followers, new buyers and most importantly new patients with a strong hope to survive with a humane treatment for a horrible disease. The product pipeline is there, the money should be there soon and the negative sentiment is too thick for the stock to remain down here much longer. The stock should be accumulated at these levels with a much more promising outlook into a new year."ÿ The writer is Arty Baker, a very good technician but also somewhat fundamental. I'll try to stop today's contribution at two cents worth. Davis

To: Alys Hall who wrote (923)	12/22/1997 7:08:00 PM
From: Cents	Read Replies (1) \| Respond to of 3702

And thank YOU too Alys! Techniclone does have one patent that I can confirm and I'm not saying that the science is bad at all...I hope that it isn't too late for Techniclone even assuming a complete change in management IS achieved! The patent... patent.womplex.ibm.com I truly feel for yourself and the other shareholders who have been led down this primrose path....Good luck on replacing the management.I would certainly love to see any gains in the war on cancer but remember even if they do get these drugs past all the trials they still have a long battle with the big drug companies. AGPH just had a lesson in that recently I believe. I am still trying to figure out why Techniclone would sell the rights to Oncolym in the FIRST place! That struck me as kind of strange for a company trying to MAKE money to sell the rights to one of their most promising products! Anyway...good luck to you and Happy Holidays! Cents